Larvol Delta - After-Almost-4-Years-FDA-Says-Mesoblast-Phase-3-Therapy-Data-Can-Support-Resubmission-For-Serious-Complications-in-Children-Following-Stem-Cell-Transplant

Ryoncil (remestemcel-L) - Mallinckrodt, Mesoblast

https://www.globenewswire.com/news-release/2024/09/30/2954846/0/en/Mesoblast-Option-to-Issue-Up-to-US-50-Million-Convertible-Notes-for-Product-Launch.html

Sep 29, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next